Aclaris Therapeutics Inc (ACRS): RA Capital Management Disposes of 1.1 Million Shares

An amended 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics Inc (NASDAQ:ACRS), decreasing its stake in the company to 1.53 million shares, which account for 7.1% of the stock’s float. As per its 13F filing for the end of June, RA Capital Management’s stake consisted of 2.63 million common shares.

Aclaris Therapeutics Inc (NASDAQ:ACRS) is a clinical-stage pharmaceutical company that works on producing various therapeutics for treating dermatological problems. Over the past 12 months, the company’s stock has gained an outstanding 122.81%. In its financial report for the second quarter of 2016, Aclaris Therapeutics disclosed a net loss of $12.87 million and a net loss per share of $0.62, which compares to a net loss of $2.59 million and a net loss per share of $1.52 for the same period of the previous year. Recently, JMP Securities initiated coverage on Aclaris Therapeutics’ stock, placing an ‘Outperform’ rating on it and a price target of $34.

Peter Kolchinsky

As per our hedge fund database, four investors that we track were long Aclaris Therapeutics Inc (NASDAQ:ACRS) at the end of June, same as a quarter earlier. Some of the bullish investors aside from RA Capital Management encompassed Kris Jenner, Gordon Bussard, and Graham Mcphail’s Rock Springs Capital Management, which held a position worth $18.47 million, and Bihua Chen’s Cormorant Asset Management, with a position valued at $16.65 million.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
RA Capital Management 0 1,530,020 0 1,530,020 1,530,020 7.1%
Peter Kolchinsky 0 1,530,020 0 1,530,020 1,530,020 7.1%
RA Capital Healthcare Fund 0 1,304,714 0 1,304,714 1,304,714 6.1%

Follow Peter Kolchinsky's RA Capital Management

Page 1 of 8 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of
1934

(Amendment No. 2)*


Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per
share

(Title of Class of Securities)

00461U105

(CUSIP Number)

September 26, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Page 2 of 8 – SEC Filing

CUSIP No. 00461U105 13G

1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

RA Capital Management, LLC


2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)   ¨
(b)   ¨

3. SEC Use Only

4. Citizenship or Place of Organization         Massachusetts

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power                           0 shares

6. Shared Voting Power            1,530,020 shares

7. Sole Dispositive Power                 0 shares

8. Shared Dispositive Power      1,530,020 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting
Person 

1,530,020 shares


10.

Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)          ¨


11.

Percent of Class Represented by Amount in Row (9)

7.1%1


12.

Type of Reporting Person (See Instructions)

IA


 

1
The reporting person is the beneficial owner of 1,530,020 shares of the Issuer’s Common Stock which constitute
approximately 7.1% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently
21,415,397 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities
and Exchange Commission (“SEC”) on August 11, 2016.

 

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 3 of 8 – SEC Filing

 

CUSIP No. 00461U105 13G

1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Peter Kolchinsky


2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)   ¨
(b)   ¨

3. SEC Use Only

4. Citizenship or Place of Organization         United States

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power                         0 shares

6. Shared Voting Power              1,530,020 shares

7. Sole Dispositive Power                 0 shares

8. Shared Dispositive Power       1,530,020 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

1,530,020 shares


10.

Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ¨


11.

Percent of Class Represented by Amount in Row (9)

7.1%1


12.

Type of Reporting Person (See Instructions)

IN


 

1
The reporting person is the beneficial owner of 1,530,020 shares of the Issuer’s Common Stock which constitute
approximately 7.1% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently
21,415,397 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities
and Exchange Commission (“SEC”) on August 11, 2016.

 

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 4 of 8 – SEC Filing

CUSIP No.   00461U105 13G

1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

RA Capital Healthcare Fund, L.P.


2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)   ¨
(b)   ¨

3. SEC Use Only

4. Citizenship or Place of Organization         Delaware

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power                         0 shares

6. Shared Voting Power              1,304,714 shares

7. Sole Dispositive Power                 0 shares

8. Shared Dispositive Power      1,304,714 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

1,304,714 shares


10.

Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ¨ 


11.

Percent of Class Represented by Amount in Row (9)

6.1%1


12.

Type of Reporting Person (See Instructions)

PN (Limited Partnership)


 

1
The reporting person is the beneficial owner of 1,304,714 shares of the Issuer’s Common Stock which constitute
approximately 6.1% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently
21,415,397 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities
and Exchange Commission (“SEC”) on August 11, 2016.

 

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 5 of 8 – SEC Filing

 

CUSIP No. 00461U105

Explanatory Note

This Amendment No. 2 to the Schedule 13G originally filed on
October 13, 2015 is being filed to report that certain of the reporting persons’ beneficial ownership has decreased by more
than five percent of a class of equity securities of the Issuer.

Item 1.

(a)       Name
of Issuer:
Aclaris Therapeutics, Inc. (the “Issuer”).

(b)       Address
of the Issuer’s Principal Executive Offices:
101 Lindenwood Drive, Suite 400, Malvern, PA 19355.

Item 2.

(a)       Name
of Person Filing:
This joint statement on Schedule 13G is being filed by RA Capital Management, LLC (“Capital”),
Peter Kolchinsky and RA Capital Healthcare Fund, L.P. (the “Fund”). Capital, Mr. Kolchinsky and the Fund are collectively
referred to herein as the “Reporting Persons.” Capital is the general partner of the Fund and serves as investment
adviser for a separately managed account (the “Account”). Mr. Kolchinsky is the manager of Capital. As the investment
adviser to the Fund and the Account, Capital may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities
Exchange Act of 1934 (the “Act”), of any securities of the Issuer owned by the Fund or the Account. As the manager
of Capital, Mr. Kolchinsky may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the
Issuer beneficially owned by Capital. Capital is a registered investment adviser within the meaning of Rule 13d-1(b)(1)(ii)(E)
and Rule 16a-1(a)(v), and Mr. Kolchinsky is a parent or control person of Capital within the meaning of Rule 13d-1(b)(1)(ii)(G)
and Rule 16a-1(a)(1)(vii). Capital and Mr. Kolchinsky disclaim beneficial ownership of the securities reported in this Schedule
13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of
the Act, and neither the filing of the Statement nor the filing of this Amendment shall be deemed an admission that either Capital
or Mr. Kolchinsky is or was the beneficial owner of such securities for any other purpose.

(b)       Address
of Principal Business Office:
The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20
Park Plaza, Suite 1200, Boston, MA 02116.

(c)        Citizenship:
Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. Mr. Kolchinsky is a United States
citizen.

(d)       Title
and Class of Securities:
Common stock (“Common Stock”)

(e)       CUSIP
Number:
00461U105

Item 3. If this statement is filed
pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 6 of 8 – SEC Filing

CUSIP No. 00461U105

Item 4. Ownership:

Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover
page(s).

(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

(c) Number of shares as to which such person has:
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

 
  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

 
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

 
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of Five Percent
or Less of a Class:

Not applicable.

Item 6. Ownership
of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 7 of 8 – SEC Filing

CUSIP No. 00461U105

Item 8. Identification and Classification
of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of
Group:

Not applicable.

Item 10. Certification:

By signing below I hereby certify that,
to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of
or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or effect.

Exhibits

1 Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule
13G filed by the Reporting Persons with the Securities and Exchange Commission on October 13,
2015
.

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)

Page 8 of 8 – SEC Filing

SIGNATURE

After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October
06, 2016

 


RA CAPITAL MANAGEMENT, LLC

By: /s/ Rajeev Shah

————————————————-

Rajeev Shah

Authorized Signatory

PETER KOLCHINSKY

/s/ Peter Kolchinsky

————————————————-

 

 

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC

Its: General Partner

By: /s/ Rajeev Shah

————————————————-

Rajeev Shah

Authorized Signatory

 

Follow Aclaris Therapeutics Inc. (NASDAQ:ACRS)